Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PFIZER, INC.

(PFE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Morgan Stanley Adjusts Pfizer's Price Target to $60 From $50, Maintains Equalweight Rating

11/29/2021 | 08:36am EST


© MT Newswires 2021
All news about PFIZER, INC.
09:35aU.S. has shipped 400 mln COVID vaccine doses worldwide -White House
RE
09:16aMARKETSCREENER’S WORLD PRESS REVIEW : January 26, 2022
06:41aBioNTech Plans 50% Workforce Boost, $57 Million Investment At German Factory
MT
03:53aCOVID-19 Severity Appears Lower With Omicron, But High Hospitalization Volume Could Str..
MT
01/25WALL STREET STOCK EXCHANGE : S&P ends down after another wild session
RE
01/25Pfizer starts clinical study on safety of Omicron-targeted vaccine
AQ
01/25US Labor Department's OSHA Revokes COVID-19 Vaccination Order for Large Employers
MT
01/25Pfizer begins testing omicron-matched COVID shots in adults
AQ
01/25Pfizer, BioNTech Launch Clinical Study of Omicron-Specific COVID-19 Vaccine
MT
01/25Pfizer, BioNTech start testing Omicron vaccine
RE
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2021 81 839 M - -
Net income 2021 22 216 M - -
Net Debt 2021 27 401 M - -
P/E ratio 2021 13,8x
Yield 2021 3,02%
Capitalization 295 B 295 B -
EV / Sales 2021 3,94x
EV / Sales 2022 3,04x
Nbr of Employees 78 500
Free-Float 59,3%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | PFE | US7170811035 | MarketScreener
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 52,54 $
Average target price 57,88 $
Spread / Average Target 10,2%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
Susan Silbermann President & General Manager-Pfizer Vaccines
Frank A. D'Amelio Chief Financial Officer & EVP-Global Supply
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-11.02%294 900
JOHNSON & JOHNSON-2.01%441 302
ROCHE HOLDING AG-8.68%304 745
ABBVIE INC.-1.71%235 287
ELI LILLY AND COMPANY-13.31%217 093
NOVO NORDISK A/S-14.94%215 777